Skip to content
The Nexus
DossierENTITY

Mapp Biopharmaceuticals

Coverage of Mapp Biopharmaceuticals in the Nexus archive.

Earliest in view: Jun 4 · 23:40 UTCMost recent: Jun 4 · 23:40 UTC
Co-mentioned in this coverage
Department of Health and Human Servicesorganization1Biomedical Advanced Research and Development Authorityorganization1MBP-134topic1Ebolatopic1Central Africaplace1
Recent coverage
  • HEALTHJun 4 · 23:40 UTCSTAT NEWS
    HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy

    HHS confirms Americans with high-risk Ebola exposures in Central Africa will receive access to an experimental antibody treatment, MBP-134, developed by Mapp Biopharmaceuticals with funding from the Biomedical Advanced Research and Development Authority. The treatment has shown promise in animal testing but has not yet been clinically proven effective in humans.

Mapp Biopharmaceuticals · Dossier · The Nexus